- |||||||||| Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_8858;
The findings of this study reveal the infrequent capture of the different components of CR endpoint in routine practice, thereby limiting the comprehensive evaluation of CR. This low coverage suggests the need for standardized assessment protocols that encompass all domains to enable accurate assessment of asthma remission.
- |||||||||| temozolomide / Generic mfg.
Journal: GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas. (Pubmed Central) - Mar 16, 2024
Further, we screened Palbociclib/BIX-02189 which dampens GINS2 expression and synergistically inhibits glioma cell proliferation with TMZ. These findings delineate a novel mechanism by which GINS2 regulates the TMZ sensitivity of glioma cells and propose a promising combination therapy to treat glioma.
- |||||||||| Journal: A pivotal decade for bispecific antibodies? (Pubmed Central) - Mar 15, 2024
Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.
- |||||||||| Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion date, Trial primary completion date, Checkpoint inhibition: Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis (clinicaltrials.gov) - Mar 15, 2024
P2, N=42, Recruiting,
These results suggest that SB202190 can inhibit ferroptosis and protect retinal ganglion cells by regulating ferritin light chain, SAT1, and SLC7A11/Gpx4 pathways and may represent a potential retina protectant. Trial completion date: Jun 2023 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jun 2030
- |||||||||| Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Journal: Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies. (Pubmed Central) - Mar 15, 2024
Based on sharp coherence in trajectories between wild KRAS and non-hotspot mutants, it is suggested that these novel mutants do not contribute to drug resistance mechanism. Overall, we provide a comprehensive understanding of the impact of non-hotspot mutations on KRAS and their potential as targets for effective cancer therapies.Communicated by Ramaswamy H. Sarma.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 15, 2024
P1/2, N=27, Active, not recruiting,
Overall, we provide a comprehensive understanding of the impact of non-hotspot mutations on KRAS and their potential as targets for effective cancer therapies.Communicated by Ramaswamy H. Sarma. Trial primary completion date: Sep 2022 --> Mar 2024
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Journal, Metastases: Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. (Pubmed Central) - Mar 15, 2024
CDC37-high mCRC patients derived more benefit from anti-VEGF therapies, including bevacizumab and regorafenib, but not from cetuximab. Molecular profiles suggested that such tumors were dependent on angiogenesis-relating pathways.
- |||||||||| adavosertib (AZD1775) / AstraZeneca
ADAVOSERTIB, A WEE1 INHIBITOR, AS A NOVEL SENOLYTICS, TARGETS THE VULNERABILITY OF LIVER CANCER INDUCED BY EPIRUBICIN (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7954;
The sustained DNA damage induced by epirubicin promoted cell senescence and activated the cGAS-STING pathway to up-regulate SASP secretion, in which inflammatory factor A induced T cell infiltration in the tumor tissue microenvironment, thus playing a stronger tumor killing role. Epirubicin-resistant liver cancer cells showed increased stemness expression, but could still be targeted and killed by Adavosertib, indicating the potential utility of Adavosertib as a treatment for refractory liver cancer.
- |||||||||| efavaleukin alfa (AMG 592) / Amgen
TARGETING IMPROVED TREG SELECTIVITY WITH THE IL-2 MUTEIN EFAVALEUKIN ALFA: RATIONALE FOR IL-2 THERAPY IN ULCERATIVE COLITIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7332;
P1b, P2
Preclinical and phase 1 results with efavaleukin alfa showed highly selective expansion of Treg with minimal effects on pro-inflammatory immune cells. These findings support the rationale and design of an ongoing phase 2b study investigating the safety and efficacy of efavaleukin alfa induction therapy in patients with moderate to severe active UC (NCT04987307).
- |||||||||| Stivarga (regorafenib) / Bayer
FACTORS ASSOCIATED WITH PROGRESSION OF GASTROINTESTINAL STROMAL TUMORS- A TERTIARY CANCER CENTER EXPERIENCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5008;
Tumor contour irregularity is associated with progression of disease, as is the presence of KIT mutation, and hyperechoic features on EUS. Hence, further validation of these variables is warranted to enable incorporation of these features in clinical decision making and risk prediction models.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
EXPLORING THE GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC INTERSECTIONS IN CHOLANGIOCARCINOMA: A DRUG DISCOVERY APPROACH (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3118;
FDA-approved and experimental drugs are available that interact with many of these targets, offering potential therapeutic benefits for patients with CCA. This underscores the unparalleled opportunity offered by the computational biology to explore and discover multi-omics targets with promising therapeutic potentials, while saving time and cost.
- |||||||||| Traficet-EN (vercirnon) / Amgen, AZD7798 / AstraZeneca
FIRST-TIME-IN-HUMAN VISUALISATION OF CCR9 EXPRESSION IN THE GUT BY POSITRON EMISSION TOMOGRAPHY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1387;
P1
Conclusion : We have developed a CCR9-specific PET tracer which potentially enables repeatable quantification of CCR9 expression in the gut. Ongoing studies will assess the effects of AZD7798 on CCR9+ cell depletion/repletion in the gut, providing critical data to support the clinical development programme.
- |||||||||| Ibrance (palbociclib) / Pfizer
Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis (Munich Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_234;
P2
This comprehensive analysis strongly suggests that LP has as profound an effect on luminal tumours as chemotherapy, with regard to proliferation decrease, immune attraction and stromal changes associated with tumor response. These results provide rationale for future chemo-sparing studies in high-risk luminal breast cancer.
- |||||||||| prednisone / Generic mfg., Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Real-life experience after 3 months with tezepelumab before marketing approval. (Pubmed Central) - Mar 13, 2024
These data indicate the role of AST in KRAS inhibitor resistance and provide predictive biomarkers for KRAS-targeted therapies in lung cancer. In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.
- |||||||||| Ibrance (palbociclib) / Pfizer, didox (NSC-324360) / Molecules for Health
Journal: Targeting the Cell Cycle, RRM2 and NF-?B for the Treatment of Breast Cancers. (Pubmed Central) - Mar 13, 2024
Our current study also reports that the CCND1 and RRM2 upregulation associated with palbociclib-resistant breast cancers decreases upon ribonucleotide reductase inhibition. Our data present a novel and promising biomarker-driven combination therapeutic approach for the treatment of ER-positive and ER-negative breast cancers that involves the inhibition of the CDK4/6-cyclinD1/pRb cell cycle axis that merits further clinical investigation in human models.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets. (Pubmed Central) - Mar 13, 2024
Current standard therapies include surgical options, systemic chemotherapy, and kinase inhibitors, like sorafenib and regorafenib...FDA-approved checkpoint inhibitors, such as atezolizumab and pembrolizumab, show efficacy, and combination therapies enhance clinical responses...It then reports a systematic analysis of the main ligand/receptor pairs and molecular pathways reported to be overexpressed in tumor cells, highlighting their potential and limitations. Finally, it discusses TGF?, one of the most promising targets of the HCC microenvironment.
- |||||||||| Review, Journal: Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. (Pubmed Central) - Mar 13, 2024
In this review, we summarize the history and current strategies for applying antiangiogenic treatment and discuss the associated challenges and opportunities, including normalizing the tumor vasculature, modulating milieu-dependent vascular heterogeneity, and targeting functions of angiocrine proteins. These new strategies could open perspectives for future vascular-targeted and patient-tailored therapy selection in CRC.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Preclinical, Journal: Sequential administration of delta-tocotrienol ameliorates radiation-induced myelosuppression in mice and non-human primates through inducing G-CSF production. (Pubmed Central) - Mar 13, 2024
To date only four recombinant growth factors, including Filgrastim (rhG-CSF), have been approved by FDA as radiomitigators to ameliorate hematopoietic acute radiation syndrome (H-ARS)...In 4.0Gy irradiated nonhuman primates, ?-T3H exhibited comparable efficacy as rhG-CSF to promote PB recovery and colony-formation of BM-HPCs. Altogether, we demonstrated that sequential administration of delta-tocotrienol ameliorates radiation-induced myelosuppression in mice and non-human primates through inducing G-CSF production, indicated ?-T3H as a promising radiomitigator for the management of H-ARS, particularly in a mass casualty scenario.
- |||||||||| ivabradine / Generic mfg.
Enrollment open: RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (clinicaltrials.gov) - Mar 13, 2024
P2, N=180, Enrolling by invitation,
Altogether, we demonstrated that sequential administration of delta-tocotrienol ameliorates radiation-induced myelosuppression in mice and non-human primates through inducing G-CSF production, indicated ?-T3H as a promising radiomitigator for the management of H-ARS, particularly in a mass casualty scenario. Not yet recruiting --> Enrolling by invitation
- |||||||||| ivabradine / Generic mfg.
Enrollment open: RECOVER-AUTONOMIC Platform Protocol (clinicaltrials.gov) - Mar 12, 2024
P2, N=380, Enrolling by invitation,
No new safety signals were identified, with most CKD patients showing renal function stability or improvement during therapy. Not yet recruiting --> Enrolling by invitation
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial termination, Metastases: PASIPHAE: HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (clinicaltrials.gov) - Mar 12, 2024
P2, N=42, Terminated,
Trial completion date: Dec 2024 --> Dec 2032 | Trial primary completion date: Dec 2024 --> Dec 2032 Active, not recruiting --> Terminated; Slow accrual
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date: S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2024
P2, N=29, Active, not recruiting,
|
